{"id":"cc-2001","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL3916385","moleculeType":"Small molecule","molecularWeight":"502.67"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Histone deacetylase inhibitors, such as CC-2001, work by blocking the action of histone deacetylases, which are enzymes that remove acetyl groups from histones. This leads to an increase in histone acetylation, which in turn promotes chromatin relaxation and increases gene expression. CC-2001 is being investigated for its potential to treat various types of cancer.","oneSentence":"CC-2001 is a histone deacetylase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:47.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT03723083","phase":"","title":"Expanded Access for CC-2001","status":"NO_LONGER_AVAILABLE","sponsor":"Celgene","startDate":"","conditions":"Dermatologic, Other","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Thalidomide, Thaliomid"],"phase":"phase_2","status":"active","brandName":"CC-2001","genericName":"CC-2001","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CC-2001 is a histone deacetylase inhibitor. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}